Investing.com - Unicycive Therapeutics (NASDAQ: UNCY) reported first quarter EPS of $-0.97, $0.64 worse than the analyst estimate of $-0.33. Revenue for the quarter came in at $675K versus the consensus estimate of $800K.
Unicycive Therapeutics's stock price closed at $1.43. It is up 169.81% in the last 3 months and up 75.16% in the last 12 months.
Unicycive Therapeutics saw 0 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Unicycive Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Unicycive Therapeutics's Financial Health score is "weak performance".
Check out Unicycive Therapeutics's recent earnings performance, and Unicycive Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar